Pet Financial News
New information from LEQEMBI® (lecanemab-irmb) part 3 Clarity AD examine and subcutaneous formulation offered at CTAD
STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) accomplice Eisai at the moment offered new information on the investigational...
Pet Financial News
New information from LEQEMBI® (lecanemab-irmb) part 3 Clarity AD research and subcutaneous formulation introduced at CTAD
STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) companion Eisai right this moment introduced new information on the investigational...
Pet Financial News
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional...
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV76% Of Patients Showed No Decline...
- Advertisement -
Pet Financial News
New information from LEQEMBI® (lecanemab-irmb) part 3 Clarity AD examine and subcutaneous formulation to be offered at CTAD
STOCKHOLM, Oct. 16, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) accomplice Eisai will current new information from the part 3 Clarity AD...
Pet Financial News
New knowledge from LEQEMBI® (lecanemab-irmb) part 3 Clarity AD research and subcutaneous formulation to be offered at CTAD
STOCKHOLM, Oct. 16, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) companion Eisai will current new knowledge from the part 3 Clarity AD...
-Advertisement-
Must read
-Advertisement-